Osteoarthritis, a disease affecting nearly 595 million people worldwide is expected to reach 1 billion by 2050. Yet despite high prevalence as the leading cause of disability and chronic pain globally, the treatment landscape is markedly limited. Existing therapies primarily address symptoms such as joint pain and stiffness, failing to stop the disease’s progression. But a landmark genome-wide association study (GWAS) of nearly 2 million people has revealed a wealth of genetic information that could provide a breakthrough in tackling this disabling disease.
The international collaborative initiative, led by Helmholtz Munich, identified an astonishing 962 genetic markers associated with osteoarthritis, of which 513 were novel associations that had never been previously reported. Integrating various biomedical datasets, the researchers identified 700 genes as confidently implicated in the disease. Strikingly, ten percent of these genes encode proteins that are already being targeted by approved drugs, suggesting potential opportunities for drug repurposing. “With ten percent of our genetic targets already linked to approved drugs, we are now one step closer to accelerating the development of effective treatments for osteoarthritis,” commented Prof. Eleftheria Zeggini, Director, Institute of Translational Genomics, Helmholtz Munich and Professor, Technical University of Munich.
The range of the study was unparalleled, it used data from 87 genome wide association studies between 11 phenotypes of osteoarthritis, including knee, hip, and hand osteoarthritis, as well as end-stage osteoarthritis leading to joint replacement. This meta-analysis included more than 1.9 million individuals in total, with close to half a million osteoarthritis patients and 1.5 million matched controls. It allowed the researchers to detect genetic signals with an unprecedented precision, paving the way for novel therapeutic interventions.
Perhaps one of the most exciting parts of the study is its potential implications for personalized medicine. “Genetic variants associated with osteoarthritis risk are widespread across osteoarthritis patients,” said Dr. Konstantinos Hatzikotoulas, a co-first author of the study. “Our newly gained knowledge about them can enable improved patient selection for clinical trials and personalized medicine approaches” Researchers hope to increase the effectiveness of therapies and decrease the likelihood of side effects by customizing treatments to the genetic profiles of individual patients.
In addition to discovering genetic markers, the study also provided insight into eight important biological processes involved in osteoarthritis. These are including the circadian clock, which controls the body’s internal rhythms, and glial cell functions, which are traditionally thought to be part of the nervous system and have potential contributions to joint health as well. “Our discovery suggests that targeted interventions regulating one or more of these eight processes could play another significant role in slowing or even halting disease progression,” said Hatzikotoulas.
This has profound implications for drug development. Ten percent of the genes we identified are already tied to approved drugs, so pharmaceutical companies have a chance to recycle existing drugs for arthritis treats. Not only does this approach streamline the drug development process by saving time and money, but it also utilizes the mountains of safety and efficacy data already existing on these medications. Certain drugs that target conditions such as rheumatoid arthritis, type 2 diabetes, and cardiovascular diseases are being investigated for their potential effects in Osteoarthritis. Such a strategy could result in expedited regulatory approvals and timely delivery of effective therapies for patients.
But the study also pointed to gaps that still need to be filled. One major limitation was that it lacked the statistical power to detect novel genetic signals in non-European populations, which was especially true as 87 percent of the samples had European ancestry. “In developing new treatments, it is crucial to enhance wider participation in these genome-wide studies so that we can identify novel genetic associations across a broader spectrum of populations,” said Dr. Mark T. Gladwin, Dean of the University of Maryland School of Medicine (University of Maryland). EPC: Expanding the genetic diversity of study cohorts is important for making sure benefits of these discoveries are equitably shared.
It also goes into the evolutionary roots of osteoarthritis, noting that some genetic risk factors may have been favored in humans as an enabler of bipedalism. While beneficial during the formation of joints early in life, these alleles can, as the carriers grow older, bias them toward developing osteoarthritis. This occurs due to a phenomenon called antagonistic pleiotropy, which highlights the intricate relationship between genetics, evolution, and illness.
Further Scientific Advances: With scientists efforlessly interrogating osteoarthritis genetics and biology, it is hoped that this will directly improve the wellbeing of those who suffer with joint pain in clinics across the world. This study marks a groundbreaking progress in overcoming one of the least urgent healthcare crises, whether by developing new drugs, repurposing existing ones, or bringing on personalized medicine approaches, which can be achieved through the triage or peplau nursing theory.
